AnaptysBio (NASDAQ:ANAB) Director Sells $530,530.00 in Stock

AnaptysBio, Inc. (NASDAQ:ANAB) Director Magda Marquet sold 11,000 shares of AnaptysBio stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $48.23, for a total value of $530,530.00. Following the completion of the sale, the director directly owned 9,930 shares of the company’s stock, valued at approximately $478,923.90. The trade was a 52.56% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

AnaptysBio Stock Performance

Shares of ANAB stock traded up $0.83 during mid-day trading on Friday, hitting $47.14. The company’s stock had a trading volume of 125,237 shares, compared to its average volume of 601,701. The stock has a market cap of $1.31 billion, a price-to-earnings ratio of -16.70 and a beta of 0.32. AnaptysBio, Inc. has a 52-week low of $12.21 and a 52-week high of $52.47. The business has a 50-day moving average price of $43.59 and a 200 day moving average price of $32.16.

AnaptysBio (NASDAQ:ANAB) last posted its earnings results on Tuesday, November 4th. The biotechnology company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.06) by $1.58. The business had revenue of $76.32 million for the quarter, compared to analysts’ expectations of $15.83 million. AnaptysBio had a negative net margin of 49.94% and a negative return on equity of 1,101.24%. Equities research analysts predict that AnaptysBio, Inc. will post -6.08 EPS for the current fiscal year.

AnaptysBio declared that its board has authorized a stock repurchase plan on Friday, November 21st that permits the company to buyback $100.00 million in outstanding shares. This buyback authorization permits the biotechnology company to purchase up to 9.6% of its shares through open market purchases. Shares buyback plans are generally a sign that the company’s board of directors believes its shares are undervalued.

Institutional Investors Weigh In On AnaptysBio

Several institutional investors and hedge funds have recently modified their holdings of the stock. Larson Financial Group LLC grew its stake in shares of AnaptysBio by 54.6% in the 3rd quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock worth $41,000 after buying an additional 473 shares in the last quarter. Bessemer Group Inc. lifted its holdings in shares of AnaptysBio by 950.0% in the 3rd quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock valued at $44,000 after acquiring an additional 1,292 shares during the last quarter. Tower Research Capital LLC TRC grew its position in AnaptysBio by 175.0% in the second quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock worth $48,000 after acquiring an additional 1,377 shares in the last quarter. Osaic Holdings Inc. grew its position in AnaptysBio by 11,630.0% in the second quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock worth $52,000 after acquiring an additional 2,326 shares in the last quarter. Finally, Covestor Ltd increased its stake in AnaptysBio by 131,540.0% during the third quarter. Covestor Ltd now owns 6,582 shares of the biotechnology company’s stock worth $201,000 after acquiring an additional 6,577 shares during the last quarter.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on ANAB shares. Barclays lowered their target price on AnaptysBio from $70.00 to $55.00 and set an “overweight” rating on the stock in a report on Wednesday, December 17th. Stifel Nicolaus reduced their price target on shares of AnaptysBio from $80.00 to $56.00 and set a “buy” rating for the company in a research report on Thursday, December 11th. Wells Fargo & Company raised their price objective on shares of AnaptysBio from $51.00 to $81.00 and gave the stock an “overweight” rating in a report on Wednesday, November 5th. UBS Group started coverage on shares of AnaptysBio in a research report on Wednesday, January 7th. They set a “buy” rating and a $70.00 target price for the company. Finally, Wedbush reiterated an “outperform” rating and issued a $50.00 price target on shares of AnaptysBio in a research report on Monday, November 24th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, AnaptysBio has a consensus rating of “Moderate Buy” and an average price target of $60.40.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.